Back to Interventions
Substance / Medication

Vemurafenib

SNOMED 702805007UMLS C3192263

Overview

Active Ingredient
vemurafenib
RxNorm CUI
1147220
Labeler: Genentech, Inc.Updated: 2025-12-01T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Malignant melanoma

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.
Mohapatra Debabrata, Gupta Aditya Kumar, Haldar Partha et al. · Pediatr Hematol Oncol · 2023
PMID: 35616365Meta-Analysis
Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
Chen P, Chen F, Zhou B · Clin Exp Dermatol · 2019
PMID: 30280426Meta-Analysis
Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
Quinn Casey, Ma Qiufei, Kudlac Amber et al. · Adv Ther · 2016
PMID: 26979173Meta-AnalysisFull text (PMC)
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
Ma Chelsea, Armstrong April W · J Dermatolog Treat · 2014
PMID: 23763243Meta-Analysis
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf Dirk, Dummer Reinhard, Flaherty Keith T et al. · Eur J Cancer · 2024
PMID: 38723373RCT
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFmutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Ascierto Paolo A, Stroyakovskiy Daniil, Gogas Helen et al. · Lancet Oncol · 2023
PMID: 36460017RCT
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E, Gogas H, Kandolf-Sekulovic L et al. · Eur J Cancer · 2023
PMID: 37482012RCT
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithV600-Mutant Melanoma.
Dummer Reinhard, Flaherty Keith T, Robert Caroline et al. · J Clin Oncol · 2022
PMID: 35862871RCTFull text (PMC)
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFmutation-positive melanoma.
Robert C, Lewis K D, Gutzmer R et al. · Ann Oncol · 2022
PMID: 35131452RCT
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
Ascierto Paolo A, Dréno Brigitte, Larkin James et al. · Clin Cancer Res · 2021
PMID: 34158360RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vemurafenib (substance)
SNOMED CT
702805007
UMLS CUI
C3192263
RxNorm CUI
1147220
Labeler
Genentech, Inc.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.